Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer.
Quick Facts
What This Study Found
FRAME-001 is a stable personalized vaccine formulation for advanced NSCLC, stable for up to 32 weeks.
Key Numbers
How They Did This
The study involved synthesizing neoantigen peptides and formulating them into a vaccine under good manufacturing practices, followed by stability testing.
Why This Research Matters
This research could lead to more effective personalized therapies for lung cancer, potentially improving patient outcomes. It also sets a precedent for developing similar vaccines for other cancers.
What This Study Doesn't Tell Us
The study primarily focuses on formulation and stability, with clinical efficacy yet to be established in trials.
Trust & Context
- Original Title:
- Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer.
- Published In:
- Pharmaceutics, 14(7) (2022)
- Authors:
- Oosting, Linette T, Franke, Katka, Martin, Michael V, Kloosterman, Wigard P, Jamieson, Jennifer A, Glenn, Laura A, de Jager, Miranda W, van Zanten, Jacoba, Allersma, Derk P, Gareb, Bahez
- Database ID:
- RPEP-06411
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-06411APA
Oosting, Linette T; Franke, Katka; Martin, Michael V; Kloosterman, Wigard P; Jamieson, Jennifer A; Glenn, Laura A; de Jager, Miranda W; van Zanten, Jacoba; Allersma, Derk P; Gareb, Bahez. (2022). Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer.. Pharmaceutics, 14(7). https://doi.org/10.3390/pharmaceutics14071515
MLA
Oosting, Linette T, et al. "Development of a Personalized Tumor Neoantigen Based Vaccine Formulation (FRAME-001) for Use in a Phase II Trial for the Treatment of Advanced Non-Small Cell Lung Cancer.." Pharmaceutics, 2022. https://doi.org/10.3390/pharmaceutics14071515
RethinkPeptides
RethinkPeptides Research Database. "Development of a Personalized Tumor Neoantigen Based Vaccine..." RPEP-06411. Retrieved from https://rethinkpeptides.com/research/oosting-2022-development-of-a-personalized
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.